Valuation: Veradermics, Incorporated

Market Cap 4.25B 3.68B 3.48B 3.15B 5.91B 407B 5.96B 41.43B 15.98B 207B 15.96B 15.61B 659B P/E 2026 *
-35.5x
P/E 2027 * -39.4x
Enterprise Value 4.25B 3.68B 3.48B 3.15B 5.91B 407B 5.96B 41.43B 15.98B 207B 15.96B 15.61B 659B EV / Sales 2026 *
-
EV / Sales 2027 * 491x
Free-Float
97.51%
Yield 2026 *
-
Yield 2027 * -
1 day+2.15%
1 week+5.46%
Current month+5.57%
1 month-7.83%
3 months+8.14%
6 months+96.76%
1 week 97
Extreme 97
105.26
1 month 93.81
Extreme 93.81
117.4
Current year 32
Extreme 32
131.24
1 year 32
Extreme 32
131.24
3 years 32
Extreme 32
131.24
5 years 32
Extreme 32
131.24
10 years 32
Extreme 32
131.24
Manager TitleAgeSince
Chief Executive Officer 31 01/12/2022
President 36 01/08/2020
Director of Finance/CFO 40 01/10/2023
Director TitleAgeSince
Director/Board Member 31 01/10/2019
Director/Board Member 84 01/09/2021
Director/Board Member 75 01/09/2021
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26 A
Montanova Capital LLC
OptionCompany 600,000 1.4361%
8/17/26 A Exercice

Founder

50,404 0.1206%
8/17/26 A Exercice

Founder

74,404 0.1781%
Change 5-day change 1-year change 3-year change Capi.($)
+2.15%+5.46% - - 4.25B
-0.19%-1.15%+50.40%+92.04% 1,015B
+0.33%-2.92%+50.06%+63.19% 642B
+0.49%+2.57%+20.47%+71.21% 463B
-0.22%+1.98%+36.33%+38.93% 353B
-0.07%-9.26%+15.16%+24.78% 265B
-0.31%+0.61%+2.73%+12.04% 254B
-1.53%-14.08%+35.91%+43.21% 206B
-1.60%-7.71%-20.79%-59.60% 191B
+0.49%-3.11%+27.72%+89.12% 182B
Average -0.07%-2.69%+24.22%+41.66% 357.45B
Weighted average by Cap. -0.10%-2.20%+33.26%+57.12%

Financials

2026 *2027 *
Net sales - 8.66M 7.5M 7.08M 6.43M 12.05M 830M 12.14M 84.42M 32.55M 421M 32.52M 31.8M 1.34B
Net income -107M -92.82M -87.62M -79.5M -149M -10.26B -150M -1.04B -403M -5.21B -402M -393M -16.61B -119M -103M -97.33M -88.31M -166M -11.4B -167M -1.16B -447M -5.78B -447M -437M -18.45B
Net Debt - -
Logo Veradermics, Incorporated
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
Employees
37
Date Price Change Volume
15/09/26 $103.89 +2.15% 938,713
14/09/26 $101.70 +2.76% 620,722
11/09/26 $98.97 +0.85% 576,027
10/09/26 $98.14 -1.54% 394,444
09/09/26 $99.67 -4.01% 553,023
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
103.89USD
Average target price
163.50USD
Spread / Average Target
+57.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MANE Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!